<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>5</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2011</Year>
        <Month>09</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Role of Intermittent Chemotherapy in the Survival of Patients with Hormone Refractory Prostate Cancer</title>
    <FirstPage>21</FirstPage>
    <LastPage>23</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Mozaffar</FirstName>
        <LastName>Aznab</LastName>
        <affiliation locale="en_US">Imam Reza Hospital and Taleghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Bahram</FirstName>
        <LastName>Samadzadeh</LastName>
        <affiliation locale="en_US">Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Assad</FirstName>
        <LastName>Moradi</LastName>
        <affiliation locale="en_US">Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Abdol Rosol</FirstName>
        <LastName>Bardideh</LastName>
        <affiliation locale="en_US">Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Jamal</FirstName>
        <LastName>Hoseini</LastName>
        <affiliation locale="en_US">Clinical Research Developemental Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Kazhal</FirstName>
        <LastName>Kaviani Moghadam</LastName>
        <affiliation locale="en_US">Statistic Department, Private Statistic Institute, Kermanshah, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>01</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Introduction: Prostate cancer is one of the most common cancers among males and the second factor resulting to death due to cancer among them.(1) The median age of its diagnosis is 65 years. The initial treatment includes androgen ablation or orchiectomy.(2, 3) In case of patient&#x2019;s hormone refractory, chemotherapy would be substituted. The objective of this study is the consideration of intermittent chemotherapy&#x2019;s role in patients&#x2019; survival and their quality of life.
Materials &amp; Methods: Since (1384,07,07), 25 patients with Hormone Refractory Prostate Cancer that referred to Taleghani &amp; Imam Reza hospital were enrolled in this study, and Taxotere, Mitoxantrone and Navalbine were prescribed along with Estramustin 140 mg/m2 and Prednisolone 10 mg/BD for 4 days respectively(4, 5, 6) and the quality of life (QoL), toxicity and overall survival were evaluated. The most toxicity included grade 2 and 3 neuropathy and neutropenia that was compliant for patients. The overall survival was 22months.
Conclusion: Intermittent chemotherapy in elderly patients with hormone refractory prostate cancer provides compliant toxicity and improvement of QoL and overall survival.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/283</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/283/276</pdf_url>
  </Article>
</Articles>
